KFDA to ban sales of sulpyrin and terfenadine

Published: 2004-11-05 07:00:00

Updated: 2004-11-05 07:00:00

The Korea Food and Drug Administration is considering taking administrative measures to ban the production and sales of sulpyrin and terfenadine due to possible side effects, as a result of its review on four substances such as sulpyrin, pemoline, terfenadine, and nandrolone.

The KFDA' move ca...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK